In situ Metabolite Mass Spectrometry Imaging: New Insights into the Adrenal Gland

Authors

Fengxia Li, Annette Feuchtinger, Axel Walch, Na Sun

Affiliation

Research Unit Analytical Pathology, German Research Center for Environmental Health, Helmholtz Zentrum München, München, Germany

Key words:

mass spectrometry imaging, adrenal gland, steroid hormones, catecholamines, metabolite imaging

received 16.12.2019

accepted 18.02.2020

Bibliography

DOI <https://doi.org/10.1055/a-1129-6947>

Published online: 29.4.2020

Horm Metab Res 2020; 52: 435–447

© Georg Thieme Verlag KG Stuttgart · New York

ISSN 0018-5043

Correspondence

Na Sun

Research Unit Analytical Pathology, German Research Center for Environmental Health, Helmholtz Zentrum München

Ingolstaedter Landstrasse 1

85764 Neuherberg

Germany

Tel.: +49 89 3187 4133, Fax: +49 89 3187 3349

na.sun@helmholtz-muenchen.de

ABSTRACT

The adrenal gland integrates catecholamine-producing neuroendocrine cells and steroid-producing cells with mesenchymal origin in a structured manner under one capsule and is a key regulator for vital bioactivity. In addition to adrenal-specific disease, dysregulation of adrenal hormones is associated with systemic effects, leading to undesirable metabolic and cardiovascular consequences. Mass spectrometry imaging (MSI) technique can simultaneously measure a broad range of biomolecules, including metabolites and hormones, which has enabled the study of tissue metabolic and hormone alterations in adrenal and adrenal-related diseases. Furthermore, this technique coupled with labeled immunohistochemistry staining has enabled the study of the pathophysiological adaptation of the adrenal gland under normal and abnormal conditions at different molecular levels. This review discusses the recent applications of in situ MSI in the adrenal gland. For example, the combination of formalin-fixed paraffin-embedded tissue microarray and MSI to tissues from patient cohorts has facilitated the discovery of clinically relevant prognostic biomolecules and generated promising hypotheses for new sights into physiology and pathophysiology of adrenal gland. MSI also has enabled the discovery of clinically significant tissue molecular (i. e., biomarker) and pathway changes in adrenal disease, particularly in adrenal tumors. In addition, MSI has advanced the ability to optimally identify and detect adrenal gland specific molecules. Thus, as a novel analytical methodology, MSI has provided unprecedented capabilities for in situ tissue study.

Introduction

Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is a technique that can directly identify and localize hundreds to thousands of molecules in a tissue sample simultaneously, including metabolites, lipids, glycans, peptides, proteins, glycolipids, and drugs and their metabolites [1]. The molecular distribution can then be correlated with the histomorphology. Unlike conventional molecular analysis methods of tissue samples [e. g., immunohistochemical (IHC) and histochemical techniques], which specifically detect individual compound localizations via antibody applications or compound classes such as polysaccharides [2], MSI-based techniques provide a simultaneous label-free detection of various types of species in the same tissue section. The cell-specific molecular signatures accessible through

MSI are hugely complementary to histopathological, IHC and other established molecular (e. g., genomics-related) data [1, 3] and therefore offer a major advantage for synergizing molecular information and morphology. Consequently, MSI has rapidly and substantially impacted basic and clinical research by identifying molecular changes associated with disease. MSI is a promising tool to expand the field of molecular pathology to improve diagnostics, prognostics, and theranostics for various tumor types [4–6].

Metabolomics can be broadly defined as the comprehensive analysis of all small molecule metabolites (i. e., ≤ 1500 Da) in a biological system. These small molecular weight compounds, including small peptides, oligonucleotides, sugars, nucleosides, organic acids, ketones, aldehydes, amines, amino acids, lipids and steroids, are present in cells, tissues and/or organisms [2]. Metabolism al-

teration occurs in various human diseases, and metabolic reprogramming is a core hallmark of cancer [7–9]. Qualitative and quantitative analysis of metabolites in biological systems are facilitated by various analytical methods, particularly MS (e. g., MALDI-MS, liquid chromatography-MS and gas chromatography-MS) [9]. Among these and other frequently used analytical assays, which usually homogenize and extract the species, MSI is the leading technique for conducting spatially resolved metabolome measurement either in fresh frozen (FF) tissue sections or formalin-fixed paraffin-embedded (FFPE) tissue [10, 11]. The preparation of FF samples can be particularly difficult (i. e., collection, handling and storage in the routine setting), whereas the vast majority of FFPE specimens (biopsies and surgical resections) are prepared in pathology laboratories. Several investigators have conducted MALDI-MSI analysis of FFPE tissue specimens (reviewed in [2, 10]). A proof-of-principal study of the spatial and chemical conservation of metabolites in archived FFPE tissue samples reports that 72 % of the m/z species overlap between FFPE and FF tissue sections [11]. Based on this work, a detailed analytical protocol for measuring molecular spatial distributions in FFPE samples using MALDI Fourier-transform ion cyclotron resonance (FTICR) MSI platform has been published [12]. The validity of the MSI protocol for FFPE tissues was demonstrated by a multicenter interlaboratory round robin study which showed a high level of between-center reproducibility of FFPE tissue metabolite data [13].

The adrenal gland plays a key role in the regulation of metabolic, cardiovascular, immune, neuronal, and mental processes through the action of two major types of hormones, steroids and catecholamines, which are produced in the outer cortex and inner medulla regions, respectively. Although both tissues of the adrenal gland descend from different origins during embryonic development and produce different types of hormones, the adrenal cortex and medulla interact with and influence each other under both healthy and pathological conditions in multiple ways, including through the blood flow that delivers steroids collected in the cortex region to the medulla and through contact between different cells at the cortical-medullary junction region [14]. In addition, the adrenal gland is in bidirectional crosstalk with the major systemic functions in the context of systemic disease, such as obesity and inflammation. Metabolites can interact directly or indirectly with molecular targets, influencing the risk and complications associated with adrenal gland disease or with adrenal dysfunction. The functional integrity of this organ system therefore is essential for hormonal homeostasis, and adrenal dysfunction may contribute to various metabolic and cardiovascular disorders and stress-related diseases [15–18].

As an emerging tool and leading technique for spatially resolved molecular assessment, MSI facilitates the study of the critical role of the adrenal gland in physiological and pathophysiological conditions. This technology fills the gap for visualizing the distributions of hormones, metabolites and drugs in the cortex and medulla of the adrenal gland and other organs or tissues from animal models to patients. Mapping metabolites and hormones to their respective pathways provides a means to image the activities of pathways in tissues [19–21]. Molecular and metabolomic pathway changes associated with adrenal diseases can be discovered under the context of their highly structured histology and interactive functionality among diverse cortical and medullary cell components by this

methodology. Importantly, the tissue section remains intact during MALDI analysis, which allows for further co-registration analyses to be conducted after the measurement has been taken. This feature therefore provides great potential for addressing highly interesting and unanswered questions in the study of the adrenal gland. The precise localization of species within specific cells may enable the study of the aforementioned spatial and functional interaction between the cortex and medulla regions. In this review, we described the recent applications of *in situ* mass spectrometry imaging in adrenal gland study, including molecular imaging of adrenal gland physiology as well as pathophysiological molecular changes of adrenal diseases. MSI provides an advanced methodology for gaining a deeper insight into adrenal function, as well as clinically relevant tissue molecular and functional adaptation in adrenal-related disease.

In situ MALDI-MSI used in tissue studies

MSI was developed from secondary ion mass spectrometry (SIMS), which introduces a pulsed ion beam moving across the sample's surface to generate a secondary ion to be directed to the mass spectrometer inlet [22, 23]. Among various sample introduction methods, matrix-assisted laser desorption/ionization (MALDI) is one of the most commonly applied ionization techniques coupled with MSI analysis, and was applied to biological tissue sections in the mid-to-late 1990s. MALDI-MSI was first used to visualize proteins and then quickly was extended to other endogenous and exogenous molecular classes by utilizing other matrices and sample preparation optimization [23–26]. MALDI-MSI has been a powerful tool for metabolome study in tissue samples. In a typical MALDI-MSI approach, tissue sections are mounted on a MALDI-compatible target carrier and then coated with a matrix [27]. The laser beam probes a specific location on the matrix-coated tissue in a predefined raster. The matrix absorbs and transfers laser energy to the analytes, thus enabling desorption and ionization. A mass spectrum is therefore generated at each measurement spot. The generated MS data can then be co-registered to the histologically stained section to enable visualization of the molecular content within a tissue morphological context [12]. Depending on the molecular classes of interest, pre-treatment of samples may be necessary to detect specific compound/compound classes or to improve sensitivity. These pre-treatments include washing to attenuate the influence of high abundance compounds on low abundant molecules, on-tissue digestion for protein or glycan analysis, and on-tissue derivatization to improve sensitivity for specific drugs or metabolites [28–30].

Post-measurement data processing and statistical analysis are a key step in MALDI-MSI analysis [23, 31]. Processing of MALDI-MSI data must consider the nature of spatially resolved mass spectra for each sample, with each mass spectrum containing hundreds to thousands of mass signals [31, 32]. The basic data processing pipeline typically involves raw data exporting, pick alignment, pick peaking, and peak annotation. Peak annotation can be done either by MS/MS experiments directly from tissue and/or by a database search of measured m/z values [23]. The commonly used public databases for MSI annotation of small molecules are HMDB (<http://www.hmdb.ca/>), METLIN (<https://metlin.scripps.edu>), lipid maps (<http://www.lipidmaps.org/>), and/or METASPACE (<http://annot.ate>).

metaspace2020.eu) [33, 34], Accurate mass measurement, coupled with tandem MS, enables small endogenous compounds to be unambiguously identified directly from the tissue [28].

Identification of metabolites is a continually developing field in metabolomics. Comparison of the mass spectral data against literature and databases is important for metabolite annotation. The continual development of metabolite databases, bioinformatics tools and MS instrumentation lead to improvements in metabolite annotations and structural identifications [35]. It is a challenge to identify and characterize the structures of unknown metabolites that are not available in databases. *In silico* analyses have been developed to assist with identification of metabolites for which MS data are not available in databases. In these cases, analysis of the fine isotope pattern of the m/z of interest using Bruker DataAnalysis and SmartFormula can be useful to predict molecular formula and possible unknown metabolite structures [11, 12]. Furthermore, it may be necessary to identify unknown metabolites using nuclear magnetic resonance (NMR) analysis or extensive chemical synthesis to enable structural comparisons using tandem mass spectrometry (MS/MS) [36, 37].

Due to the amount of MSI data (i. e., in the gigabyte range), the processing and handling of the data have become computationally demanding. Commercial software packages, such as Multimagging (Imabiotech, France) or SCiLS (Bruker Daltonics, Germany), can handle terabyte-sized, multi-sample data sets and include many statistical tools for biomarker discovery [23]. In addition to classical statistical tests, supervised and/or unsupervised statistical analyses have been applied to MSI data analysis [31, 38–42]. A schematic of the MALDI-MSI concept with post-measurement data handling is provided in ► Fig. 1, [43].

The application of MSI to research questions of biological and clinical significance has increased exponentially since the introduction of the technology [28]. MSI has been applied by many studies

to investigate complex structures in tissue, including in brains, eyes, joints, wounds and atherosclerotic plaques. Oncology, however, has been and still is the driving field for MSI. In this context, MSI has been used to extract tumor-specific molecular information for the purpose of biomarker discovery to improve diagnosis and prognosis as well as to study intra-tumor heterogeneity and classification of tumor margins. Its applications generally cover all stages of translational research from pre-clinical to clinical studies [4–6, 23, 44–47].

MSI analysis has enabled access to a variety of molecules in the adrenal gland. In the healthy human adrenal gland, a wide spectrum of endogenous metabolites, including catecholamines, steroid and steroid metabolites, nucleotide derivatives, intermediates of glycolysis and the tricarboxylic acid (TCA) cycle and lipids and fatty acids, have been measured by MALDI-FTICR-MSI analysis [20]. Under pathophysiological conditions, endogenous metabolites and various hormones and their derivatives (e. g., 18-hybrid steroids) also were detected in FFPE specimen from adrenal tumors [21, 48, 49]. These findings have led to deeper insight into the metabolites and hormone adaptation in the functional and dysfunctional adrenal gland and adrenal tumors as will be shown in later cases. Specific to the adrenal gland, a few studies also have focused on the improvement of the detection and localization of adrenal-specific hormones, including for catecholamines [50–52] and particularly for poorly ionized and isomeric steroids, leading to new hypothesis of adrenal disease pathogenesis, as will be reported later in this review [49, 52, 53].

MSI method adaption for visualizing steroids in adrenal cortex (FF tissue)

Although high-resolution mass analyzers such as FTICR-MS (i. e., 100 000 mass resolution for common tissue metabolites) allow relatively accurate and confident assignments of ion peaks to chem-

► **Fig. 1** Representation of the matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) workflow: matrix deposition, in situ laser desorption mass spectrometry analysis, hematoxylin and eosin (H & E) staining, and co-registration of MSI data with the H & E image to achieve H & E-guided extraction of mass spectra information. (Reprinted from [43] with permission from Elsevier) [rerif].

Fig. 2 Product ion spectra of GirT-aldosterone and GirT-cortisone (GirT-E) standards. MS² spectra of *m/z* 474 and presumed structures show similar fragmentation patterns for **a** GirT-aldosterone and **b** GirT-cortisone. MS³ spectra of *m/z* 415 show characteristic fragmentation patterns for **c** GirT-aldosterone and **d** GirT-cortisone. (Reprinted from [52] with permission from American Chemical Society) [rerif].

ical formulas, a lack of detection sensitivity can hinder its application to the molecular imaging due to low ionization efficiency, ion suppression by abundant species, and background spectral interference from either the matrix and/or tissue components [51, 52]. Low sensitivity in the adrenal gland MSI study is particularly prominent for neutral steroids as they have relatively low abundance, poor ionization yields (i. e., lack of hydrogen donor or acceptor moieties), and susceptibility to ion suppression of lipids and proteins [53]. Another challenge for MSI molecular assignment is that it cannot discriminate between structural isomers, which occur frequently for steroids [52]. Four pairs of structural isomers can be found in human adrenocortical steroidogenesis pathways, including 18-hydroxyl corticosterone and cortisol, cortisone and aldosterone, corticosterone and 11-deoxycortisol, and 11-deoxycorticosterone and 17-hydroxyprogesterone. Differentiating these steroids during in situ on-tissue MSI analysis is challenging but provides the opportunity to study their biological activity and communication within their producing context. With regard to these two major challenges, in situ chemical derivatization in combination with tandem MS techniques has demonstrated its usefulness in steroid imaging in

the adrenal gland. Chemical derivatization introduces polar functional groups resulting in enhanced ionization yields, whereas tandem mass fragmentation produces characteristic fragments that are particularly useful for structure identification and differentiation of structural isomers.

To enhance the sensitivity of neutral steroid MSI analysis, Cobice et al. explored derivatization methods and found that on-tissue chemical derivatization using GirT reagent has the highest sensitivity for 11-dehydrocorticosterone and corticosterone, achieving low limit of detection and high signal-to-noise ratio (> 100) [53]. Such derivatization reactions target the α,β -unsaturated ketone at C3 in the steroid A-ring. Cobice et al. used collision induced dissociation (CID)/liquid extraction surface analysis to confirm the structure of the generated compounds. CID of the GirT derivatives produced a series of fragment ions characterized by the loss of the quaternary amine tag $[M - 59]^+$ and carbon monoxide $[M - 87]^+$ of the derivatized group. This method was applied to image 11-dehydrocorticosterone and corticosterone distribution in the mouse adrenal gland and brain. MSI analysis of the mouse brain with glucocorticoid-amplifying enzyme 11 β -HSD1 deficiency or inhibition

► **Fig. 3** Unsupervised hierarchical clustering reveals the molecular structures of the adrenal gland. These structures match well the histology of the adrenal gland in level 1 (two classes separate the cortex and medulla) and level 2 [four classes separate the zona glomerulosa (ZG), zona fasciculata (ZF), zona reticularis (ZR), and medulla], and identified additional distinct molecular layers in level 3 (10 molecular classes). Scale bars: 1 mm. ZG: Zona glomerulosa; ZF: Zona fasciculata; ZR: Zona reticularis; H & E: Hematoxylin and eosin. (Reprinted from [20] by permission of Oxford University Press) [rerif].

revealed sub-regional corticosterone/11-dehydrocorticosterone ratio changes, and accumulation of 7-ketocholesterol as the alternative 11 β -HSD1 substrate. This MSI data was validated by liquid chromatography (LC)-MS/MS in whole brain homogenates with high correlation.

Recently, GirT derivatization followed by tandem MSI (MS/MS: MS² and MS/MS/MS: MS³) successfully differentiated aldosterone from its isomer cortisone, which shows a different distribution pattern. MS³ was necessary for generating characteristic fragments to distinguish aldosterone from cortisone, as shown in ► **Fig. 2**, [52]. As the first studies to visualize the localization of aldosterone on a frozen rat adrenal section, MSI analysis confirmed its production in the ZG layer following a sodium-deficient diet [49]. GirT derivatization has also enabled the visualization of other steroids of GirT-corticosterone, GirT-18-hydroxycorticosterone and GirT-progesterone [49]. This method has been applied to the study of aldosterone-producing cell clusters (APCCs), which occur in more than 80 % of adult adrenals (> 30 years old), and their relation to APAs as will be discussed later [49, 54]. Subsequently, this derivatization and MS³-based method was extended to separate not only aldosterone but also cortisol from their isomers, cortisone and 18-oxocorticosterone, respectively. Cortisol distribution was visualized for the first time in the human adrenal gland [52].

For the detection of steroids, publications are mainly focused on chemical derivatization using FF tissue samples which could increase ionization efficiency of steroids. Nevertheless, previous studies have demonstrated that certain steroids can be detected in FFPE tissue without specific chemical derivatization [21, 48].

Molecular imaging of adrenal gland physiology by MSI (FF tissue)

The normal functional anatomy of the adrenal gland has been studied using MSI techniques to look into their metabolites and hormone profile in situ. Localization of cholesterol and corticosterone with a sub-cellular spatial resolution was demonstrated in the rat adrenal cortex using imaging time-of-flight secondary ion mass spectrometry (TOF-SIMS) [55]. Wu et al. applied desorption electrospray ionization (DESI) imaging (positive ion mode, raster size 200 μ m) to porcine and rabbit adrenal gland tissue and determined that the distribution of the small hormones epinephrine and norepinephrine enriched in the medulla layer [56]. Using MALDI-FTICR-MSI in both the positive and negative ion modes (raster size 200 μ m), Wang et al. determined the spatial distribution pattern of 544 lipids and 11 non-lipid metabolites in porcine adrenal glands, and showed that many classes of lipids had distinct distribution patterns in different functional zones of the adrenal gland [57]. Another study has in-

Fig. 4 **a** The results of orthogonal partial least squares discriminant analysis (ortho-PLSDA), which identified separate clusters for KCNJ5- and CACNA1D-mutated aldosterone-producing adenomas (APAs) based on metabolome profiles. **b** Significant difference in metabolites related to purine metabolism were found between KCNJ5- and CACNA1D-mutated APAs (adjusted $p = 0.010$, 0.003 , and 0.047 , respectively). **c** Significant changes in the intensities of 18-oxocortisol ($p = 0.020$) and 18-hydroxycortisol ($p < 0.001$) were identified between KCNJ5- and CACNA1D-mutated APAs. Mann–Whitney U-tests were used for statistical analysis. * $p < 0.05$; ** $p < 0.01$. (Reprinted from [48] with permission from American Society for Clinical Investigation) [rerif].

creased the molecular specificity and sensitivity in the rabbit adrenal gland using sodium-doped gold-assisted LDI-enhanced MSI (high lateral resolution of $25 \mu\text{m}$) to show distributions of cholesterol, different cholesterol esters (CE) and triacylglycerols (TAGs) [58].

Normal human adrenal gland molecular imaging has been performed by Sun et al. using a comprehensive MADLI-FTICR-MSI [20]. As mentioned before, a broad spectrum of metabolites and hormones, including epinephrine, norepinephrine, dehydroepiandrosterone sulfate, pregnenolone sulfate, cholesterol sulfate, AMP, ADP, ATP, UDP-glucose, UDP-*N*-acetylglucosamine, glucose monophosphate, citrate, palmitic acid, adrenic acid, and phosphatidylinositol, can be measured via this method. Functional adrenal zonation assessed by IHC demonstrates an exact co-localization of sulfated steroid hormone with zone specific IHC markers in the human adrenal gland. A clear separation of the cortex and medulla was observed at the level of individual metabolites by heat map-based clustering analysis of discriminative metabolites. At the comprehensive metabolic pathway level, pathway enrichment analysis revealed enhanced steroid hormone and fatty acid synthesis in the adrenal cortex, which is in line with the known steroid hormone production in the cortex. Elevated activity of the pentose phosphate pathway and glycolysis and nucleotide metabolism in the medulla was found, reflecting the high energy consumption in the medulla. A spatial segmentation map based on unsupervised hierarchical clustering generated not only a clear separation between the cortex and medulla (► Fig. 3, level 1) but also a virtually molecular-based map that matched perfectly with the histological morphological features of adrenal gland, including the zona glomerulosa (ZG), zona fasciculata (ZF), zona reticularis (ZR), and medulla (► Fig. 3, level 2). Further improved spatial segmentation created

10 individual molecular-defined zones corresponding to functionally distinct parts that are not completely reflected by the histological layers of the adrenal gland (► Fig. 3, level 3) [20]. Among these identified zones, molecular zones 1–6 represented the cortex area and molecular zones 7–10 corresponded to the medulla area. The relevance of molecular-based zonation, although not well-elucidated, is likely to reflect functional adaptation to the interplay between the adrenal medulla and cortex.

Molecular Imaging of whole-body animal tissue section (FF tissue)

MSI has also been used for whole-body sections from different model animals such as rats, mice [59, 60]. Molecular structures enriched in the adrenal gland could be accessible via whole-body molecular imaging. As an example, MALDI-MSI of mice has identified one phospholipid (m/z 810.60) enriched in the adrenal gland [61]. Whole-body MSI simultaneously detects the presence of molecules in different organs, thus providing a way for studying the relation of adrenal gland with other organs. Another study observed the presence of the antitumor candidate drug (S)-(+)-deoxytylophosphorinidine (CAT) after drug dosing in a whole-body molecular image via air flow-assisted ionization in the DESI mode (AFADESI)-imaging mass spectrometry (IMS) [62]. High drug concentration in the adrenal gland was found 20 min after dosing and was steadily conserved 2 hours after dosing. The visualization of exogenous drug disposition in multiple organs in the whole-body section through MSI allows the direct discovery of the organ targeted by drug candidate. The prediction of pharmacological activity and potential toxicity could be one potential application of such method.

Fig. 5 **a** Immunohistochemistry (IHC) for CYP11B2 in human adrenalectomized samples. Cases 1–4 (blue background), case 5 (orange background) and cases 6–8 (green background) show IHC results for aldosterone-producing cell clusters (APCCs; arrowheads), possible APCC-to-aldosterone-producing adenoma (APA) transitional lesions (pAATLs), and APAs, respectively. In cases 3–8; T: Tumor area within red dotted lines, NT: Non-tumor area outside of the red dotted line. Bars represent 1 mm. **b** Matrix-assisted laser desorption/ionization (MALDI) imaging of APCCs (cases 1–4, blue background), pAATLs (case 5, orange background), and APAs (cases 5–8, green background) using Fourier-transform ion cyclotron resonance mass spectrometry (FT-ICR-MS). $GirT$ -18-oxoF shows the distribution of derivatized 18-oxocortisol. $GirT$ -aldo/cortisone demonstrates the distribution of derivatized aldosterone and cortisone. In cases 1–4, white arrowheads correspond to black arrowheads indicating APCCs in ▶ Fig. 5a. In cases 3–8, T (tumor region within orange dotted lines) and NT (non-tumor region outside of the orange dotted line) correspond to CYP11B2 staining in ▶ Fig. 5a. Bars represent 1 mm. (Reprinted from [49] with permission from Wolters Kluwer Health, Inc.) [rerif].

Clinicopathologic application of MSI in the study of adrenal tumors

The dysfunction of the adrenal gland could present as an excess or insufficiency of adrenal hormones in conjunction with relevant symptoms. For example, overproduction of glucocorticoids causes Cushing's syndrome, whereas excessive aldosterone results in hyperaldosteronism [63–65]. The most common benign adrenal tumor is adrenocortical adenoma, most of which are aldosterone-producing or cortisol-producing adrenocortical adenoma. Adrenocortical carcinoma (ACC) is a rare endocrine tumor with great clinical significance due to its high malignancy potential [66]. Pheochromocytomas are tumors of chromaffin cells, which most commonly arise in the adrenal medulla and are usually not metastatic [67, 68]. In all cases, adrenal diseases and tumors have the potential to impair quality of life and may be life-threatening.

In situ metabolomics of aldosterone-producing adenomas (APAs) by MSI and its clinical implications (FFPE tissue)

MALDI-FTICR-MSI was applied to a cohort of 136 FFPE tissue cores of patients with a unilateral primary aldosteronism, which allowed for a comprehensive metabolite profile analysis and association with genotype/phenotype, IHC of steroidogenic enzymes and clinical features/outcomes [48]. This study identified 137 significantly

different metabolites between KCNJ5- and CACNA1D-mutated APAs, including metabolites associated with steroidogenesis and purine metabolism. An increase in purine synthesis in APAs with KCNJ5 mutations could reflect the promotion of cell proliferation, which is also connected to the larger tumor size observed in KCNJ5-mutated APAs (▶ Fig. 4). High levels of 18-oxocortisol and 18-hydroxycortisol were found in KCNJ5-mutated APAs (▶ Fig. 4). Accordingly, high plasma levels of 18-oxocortisol and 18-hydroxycortisol were identified in patients with KCNJ5-mutated APA and were shown to be predictive of KCNJ5 mutation. Distinct metabolome profiles between these two gene mutations were further supported by orthogonal partial least squares discriminant analysis (ortho-PLSDA) clustering (▶ Fig. 4). Regarding steroids and steroidogenesis enzymes, 18-oxocortisol and 18-hydroxycortisol were inversely correlated with CYP11B1 but not CYP11B2 in APA tissues, which might be explained by an overall high expression of CYP11B2 above a threshold critical for detecting 18 steroid level differences. CYP11B2 has been shown to convert 11-deoxycortisol to 18-oxocortisol and 18-hydroxycortisol, whereas CYP11B1 only produces 18-hydroxycortisol [69]. Moreover, both 18-oxocortisol intensity and CYP11B1 expression levels in tumor tissue are predictive of the clinical outcome, independent of other clinical parameters [48]. For example, complete clinical success after surgery was linked to high intensity of 18-oxocortisol or low staining of

► **Fig. 6** Hierarchical clustering and component analysis demonstrated different metabolic profiles in APCC subgroup 1, APCC subgroup 2 and APAs. **a** Peak lists with respective intensities were uploaded to MetaboAnalyst. Each colored cell corresponds to an intensity value, with samples in rows and features in columns. Euclidean distance and Ward's method were applied for cluster analysis. **b** Component analysis using sPLSDA identified 3 patterns of metabolites comprising 2 subgroups of clearly separated APCCs (subgroup 1 and subgroup 2) and the APA group. **c** CYP11B2 (aldosterone synthase) immunohistochemistry of adrenal samples included in the metabolic analyses showing APCCs in subgroup 1, APCCs in subgroup 2 and APAs. ROI (region of interest) identification numbers are shown for each APCC analyzed. (Reprinted from [72] with permission from Wolters Kluwer Health, Inc.) [rerif].

CYP11B1, demonstrating the importance of CYP11B1 over CYP11B2 in tumor tissue with regard to the clinical outcome. This association between 18 steroid levels, CYP11B1 and clinical outcome also may be related to the glucocorticoid co-secretion observed in APAs, and also may be related to “Connshing” syndrome [70, 71].

MSI imaging in the adrenal cortex suggests pathophysiological progression from aldosterone-producing cell clusters (APCCs) to APA (FF and FFPE tissue)

APCCs can be identified by IHC staining of strong aldosterone synthase (CYP11B2) expression without expression of steroid 11 β -hy-

droxylase (cortisol-synthesizing enzyme, CYP11B1), even in the non-primary aldosteronism (AP) producing adult cortex (► **Fig. 5a**, cases 1–4). Thus, APCCs seem to produce aldosterone autonomously. The accumulation of aldosterone and 18-oxocortisol in CYP11B2-expressive lesions (APCC) was confirmed by Sugiyama et al. by visualizing GirT derivatized aldosterone on FF adrenal samples [49]. The distribution patterns of 18-oxocortisol and aldosterone in APCC and APA tissues (► **Fig. 5b**) have led to a progressive development hypothesis of APA generation in which APCCs develop into APAs via APCC-to-APA transitional lesions (pAATLs: ► **Fig. 5b**, case 5). These pAATLs can be divided into a sub-capsular APCC-like region and an inner APA-like region. The APCC-like region of a

pAATL consists of aldosterone-producing cells like an APCC, whereas the APA-like region of a pAATL contains both aldosterone- and cortisol-producing cells like a small size APA. In one case with a large CYP11B2-positive APA (► Fig. 5b, case 8), both an aldosterone-producing area and a nonfunctional area without aldosterone were identified via imaging; the latter nonfunctional area may have been due to a lack of precursor steroids, including progesterone. Both plasma 18-oxocortisol and aldosterone levels are increased in pa-

tients with APAs. This study found accumulation of 18-oxocortisol in the CYP11B2-positive APCC regions, as well as in the APA regions, with either heterogeneous or relatively homogenous distributions (► Fig. 5b) [49]. By comparing the steroid distributions imaged via MSI analysis (► Fig. 5b) with the distributions of steroidogenesis enzymes identified via IHC staining (► Fig. 5a), this study generated the hypothesis that 18-oxocortisol in the APCC region results from 18-oxidization of cortisol by CYP11B2, and that the cortisol

► **Fig. 8** The distribution of 4-(N-methyl)pyridinium boronic acid [4-(N-Me)PyB(OH)₂] derivatized catecholamines in the porcine adrenal gland was analyzed by GCIB-ToF-SIMS (30 μm per pixel). **a** Hematoxylin and eosin (H & E) staining of adrenal cortex and medulla. **b** An unidentified peak with *m/z* 753.5. **c** Norepinephrine-4-(N-Me)PyB(OH)₂ with *m/z* 271.1. **d** Dopamine-4-(N-Me)PyB(OH)₂ with *m/z* 255.1. **e** Epinephrine-4-(N-Me)PyB(OH)₂ with *m/z* 285.1. **f** Fragment ion of epinephrine/norepinephrine-4-(N-Me)PyB(OH)₂. **g** and **h** Merged ion images of norepinephrine-4-(N-Me)PyB(OH)₂ (red), epinephrine-4-(N-Me)PyB(OH)₂ (green), dopamine-4-(N-Me)PyB(OH)₂ (blue, **g**) or unidentified peak with *m/z* 753.5 (blue, **h**). (Reprinted from [51] with permission from American Chemical Society) [rerif].

diffused to the APCC region from the surrounding ZF. The hypothesis that cortisol moves from CYP11B1-active region to APCCs and that cortisol is further oxidized by CYP11B2 into 18-oxocortisol and 18-hydroxycortisol were further supported by visualizing cortisol in the human adrenal gland as mentioned before [52]. Cortisol were found to be absent in all APCCs where aldosterone was accumulated.

The most recent publication of Sun et al. used in situ metabolic imaging analysis by MALDI-FT-ICR-MSI of FFPE adrenals resected from patients with unilateral primary aldosteronism to investigate the potential existence of diverse metabolic phenotypes of APCCs [72]. The analysis covered a wide range of central metabolic and steroid hormone biosynthesis pathways and determined heterogeneous patterns of metabolites associated with APCCs.

Specific distribution patterns of metabolites were associated with APCCs and classified 2 separate APCC subgroups (subgroups 1 and 2) indistinguishable by CYP11B2 immunohistochemistry.

Metabolic profiles of APCCs in subgroup 1 were tightly clustered and distinct from subgroup 2 and APAs. Multiple APCCs from the same adrenal displayed metabolic profiles of the same subgroup (► **Fig. 6**). Metabolites of APCC subgroup 2 were highly similar to the APA group and indicated enhanced metabolic pathways favoring cell proliferation compared with APCC subgroup 1. In conclusion, the results demonstrate specific subgroups of APCCs with strikingly divergent distribution patterns of metabolites. One subgroup displays a metabolic phenotype convergent with APAs and may represent the progression of APCCs to APAs.

Prognostic relevance of steroid sulfation detected by MSI in adrenocortical carcinoma (ACC) (FFPE tissue)

Molecules measured by MSI could be used in conjunction with genomic and RNA expression data to determine the molecular phenotype of tumors. As shown in ► **Fig. 7a**, MALDI-FTICR-MSI analysis identified the molecular phenotype of 72 ACCs based on steroid

hormone metabolites [21]. In this study, high levels of estradiol sulfate (E2S) and estrone-3-sulfate (E1S) were significantly associated with a good ACC prognosis via both univariate Kaplan-Meier analysis and after multivariate adjustment for tumor stage, age, and sex (► Fig. 7c and d). This finding supports the idea that active steroid sulfation is a marker of a less aggressive ACC phenotype. Moreover, the expression of sulfotransferase SULT2A1 in the same tissue samples had similar prognostic power. This finding was validated in two published data sets, and suggests that SULT2A1 is the enzyme responsible for the synthesis of E1S and E2S. Beyond the known steroid sulfates, disulfated steroid estradiol-17 β -3,17-disulfate (E2S2) also was found in six samples, first by searching for the calculated theoretical mass in the measured spectrum and then validating by MS/MS. Its presence in these six patients was associated with a particularly poor overall survival (► Fig. 7e). Multiple membrane-delimited vacuoles were found only in these tumors with E2S2, supporting the intracellular accumulation of E2S2 (► Fig. 7b). This study thus highlights the potential of steroid hormone sulfation to predict a patient's prognosis and to stratify patients by treatment.

MSI of catecholamines in the adrenal medulla (FF tissue)

Although catecholamines in the medulla region are accessible via different MSI techniques such as DESI-MSI or high-resolution MALDI-FTICR-MSI, as previously mentioned [20, 56], a few studies have also applied derivatization for catecholamines visualization. Manier et al. [50] improved the sensitivity of the medulla origin hormones dopamine, epinephrine and norepinephrine by pre-coating the target with 4-hydroxy-3-methoxycinnamaldehyde (CA) as a derivatization reagent in a MALDI ion trap MSI analysis. The signals for these three target compounds from underivatized analyses were very low with a non-specific distribution in their analysis, indicating insufficient sensitivity for distinguishing target compounds from the chemical background or matrix interference. In contrast, derivatization followed by MALDI-MSI with MSⁿ analysis resulted in substantially improved sensitivity, allowing a clear visualization of the respective hormones in situ in the medulla region. Particularly, MS³ was necessary to produce the specific fragments to enable visualization of derivatized norepinephrine. A more accurate localization of dopamine, epinephrine and norepinephrine in the modular region also was achieved in another study [51]. By applying 4-(*N*-methyl)pyridiniumboronic acid [4-(NMe)PyB(OH)₂] derivatization, both LDI-TOF-MSI and gas cluster ion beam (GCIB)-TOF-SIMS analysis yielded a similar characteristic spatial distribution of epinephrine, norepinephrine and dopamine in porcine adrenal gland tissue sections; these compounds localize in the peripheral, central and entire medulla region, respectively, as shown in ► Fig. 8, [51]. In another study, the derivatization reagent *p*-*N,N,N*-trimethylammonioanilyl *N'*-hydroxysuccinimidyl carbamate iodide (TAHS) was applied to successfully discriminate enriched catecholamine species in the pheochromocytoma region [52].

MSI for utilizing the pheochromocytoma (PC12) cell model (FF tissue)

A few studies have applied MSI techniques, mainly secondary ion (SI) MSI, for measuring the pheochromocytoma (PC12) cell model, which is widely used as a model system for studying exocytosis [73]. PC12

cells release catecholamines by exocytosis and differentiate into neuron-like cells upon treatment with nerve growth factor [74]. TOF-SIMS was used to image lipids fragments in freeze fractured rat pheochromocytoma (PC12) cells on a single-cell level [73–75]. Dopamine localization was identified in the vesicular compartments of pheochromocytoma (PC12) cells by correlating TEM and NanoSIMS images of single vesicles [76]. In a drug-related study, a decrease of lipids in PC12 cells treated with cisplatin was observed, suggesting that cisplatin affects exocytotic release by alternating cell membrane lipids [77].

Conclusion and Perspectives

The innovative and continuously developed MALDI-MSI technology has demonstrated great power for both basic study and clinical/pre-clinical study of the adrenal gland under both physiological and pathophysiological conditions. Its application has enabled a deeper understanding of the molecular adaptation underlying adrenal diseases, particularly adrenal tumors. Retrospective studies of patient cohorts allows for the investigation of tumorigenesis and clinically relevant abnormal steroidogenesis at the molecular level, adding one more level of information to existing enzyme and genetic data. Clinically relevant patient stratification of adrenal tumors via molecular identification may pave the way for novel and robust tissue biomarker based precision medicine and therapeutic decision making. Future studies may extend currently existing clinicopathologic application of simultaneous imaging of hormones, metabolites, drugs and their metabolites in the adrenal gland and other endocrine organs from patients and animal models. In the future, prospective cohort studies can also validate steroid fingerprinting as markers for malignancy and the staging of newly detected adrenal neoplasms. In addition to diagnostics, steroid metabolism may serve as an objective and refined method for monitoring the treatment of adrenal patients. Finally, the extension of this application to not only adrenal disease but also other systemic diseases involving adrenal dysfunction has promising possibilities.

Funding Information

Deutsche Forschungsgemeinschaft (CRC/TRR 205 “The Adrenal: Central Relay in Health and Disease”, projects S01 to A.W.), Deutsche Krebshilfe (no. 70112617 to A.W.)

Conflicts of Interest

The authors declare that they have no conflict of interest.

References

- [1] Dilillo M, Heijs B, McDonnell LA. Mass spectrometry imaging: How will it affect clinical research in the future? *Expert Rev Proteomics* 2018; 15: 709–716
- [2] Buck A, Aichler M, Huber K et al. In situ metabolomics in cancer by mass spectrometry imaging. *Adv Cancer Res* 2017; 134: 117–132

- [3] Qi M, Philip MC, Yang N et al. Single cell neurometabolomics. *Acs Chem Neurosci* 2018; 9: 40–50
- [4] Arentz G, Mittal P, Zhang C et al. Applications of mass spectrometry imaging to cancer. *Adv Cancer Res* 2017; 134: 27–66
- [5] Smith A, Piga I, Galli M et al. Matrix-assisted laser desorption/ionisation mass spectrometry imaging in the study of gastric cancer: A mini review. *Int J Mol Sci* 2017; 18: pii E2588. doi: 10.3390/ijms18122588
- [6] Phillips L, Gill AJ, Baxter RC. Novel prognostic markers in triple-negative breast cancer discovered by MALDI-mass spectrometry imaging. *Front Oncol* 2019; 9: 379
- [7] Peng X, Chen Z, Farshidfar F et al. Molecular Characterization and clinical relevance of metabolic expression subtypes in human cancers. *Cell Rep* 2018; 23: 255–269.e254
- [8] Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell* 2011; 144: 646–674
- [9] Papathomas TG, Sun N, Chortis V et al. Novel methods in adrenal research: A metabolomics approach. *Histochem Cell Biol* 2019; 151: 201–216
- [10] Patel E. Fresh frozen versus formalin-fixed paraffin embedded for mass spectrometry imaging. *Methods Mol Biol* 2017; 1618: 7–14
- [11] Buck A, Ly A, Balluff B et al. High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples. *J Pathol* 2015; 237: 123–132
- [12] Ly A, Buck A, Balluff B et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. *Nat Protoc* 2016; 11: 1428–1443
- [13] Buck A, Heijs B, Beine B et al. Round robin study of formalin-fixed paraffin-embedded tissues in mass spectrometry imaging. *Anal Bioanal Chem* 2018; 410: 5969–5980
- [14] Haase M, Willenberg HS, Bornstein SR. Update on the corticomedullary interaction in the adrenal gland. *Endocr Dev* 2011; 20: 28–37
- [15] Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management: A clinical approach. *Endocrinol Metab Clin North Am* 2019; 48: 681–700
- [16] van der Heijden C, Keating ST, Groh L et al. Aldosterone induces trained immunity: The role of fatty acid synthesis. *Cardiovasc Res* 2020; 116: 317–328
- [17] Liu B, Zhang TN, Knight JK et al. The glucocorticoid receptor in cardiovascular health and disease. *Cells* 2019; 8: pii E1227. doi: 10.3390/cells8101227
- [18] Russell G, Lightman S. The human stress response. *Nat Rev Endocrinol* 2019; 15: 525–534
- [19] Dekker TJ, Jones EA, Corver WE et al. Towards imaging metabolic pathways in tissues. *Anal Bioanal Chem* 2015; 407: 2167–2176
- [20] Sun N, Wu Y, Nanba K et al. High-resolution tissue mass spectrometry imaging reveals a refined functional anatomy of the human adult adrenal gland. *Endocrinology* 2018; 159: 1511–1524
- [21] Sun N, Kunzke T, Sbiera S et al. Prognostic relevance of steroid sulfation in adrenocortical carcinoma revealed by molecular phenotyping using high-resolution mass spectrometry imaging. *Clin Chem* 2019; 65: 1276–1286
- [22] Heeren RMA. Getting the picture: The coming of age of imaging MS. *International J Mass Spectrom* 2015; 377: 672–680
- [23] Vaysse PM, Heeren RMA, Porta T et al. Mass spectrometry imaging for clinical research - latest developments, applications, and current limitations. *Analyst* 2017; 142: 2690–2712
- [24] Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. *Anal Chem* 1997; 69: 4751–4760
- [25] Chaurand P, Schwartz SA, Billheimer D et al. Integrating histology and imaging mass spectrometry. *Anal Chem* 2004; 76: 1145–1155
- [26] Todd PJ, Schaaff TG, Chaurand P et al. Organic ion imaging of biological tissue with secondary ion mass spectrometry and matrix-assisted laser desorption/ionization. *J Mass Spectrom* 2001; 36: 355–369
- [27] Abdelhamid HN. Organic matrices, ionic liquids, and organic matrices@nanoparticles assisted laser desorption/ionization mass spectrometry. *Trends Anal Chem* 2017; 89: 68–98
- [28] Norris JL, Caprioli RM. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. *Chem Rev* 2013; 113: 2309–2342
- [29] Cobice DF, Goodwin RJ, Andren PE et al. Future technology insight: mass spectrometry imaging as a tool in drug research and development. *Br J Pharmacol* 2015; 172: 3266–3283
- [30] Duenas ME, Larson EA, Lee YJ. Toward mass spectrometry imaging in the metabolomics scale: Increasing Metabolic Coverage Through Multiple On-Tissue Chemical Modifications. *Front Plant Sci* 2019; 10: 860
- [31] Balluff B, Schone C, Hofler H et al. MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications. *Histochem Cell Biol* 2011; 136: 227–244
- [32] McDonnell LA, van Remoortere A, de Velde N et al. Imaging mass spectrometry data reduction: Automated feature identification and extraction. *J Am Soc Mass Spectrom* 2010; 21: 1969–1978
- [33] Wishart DS, Feunang YD, Marcu A et al. HMDB 4.0: The human metabolome database for 2018. *Nucleic Acids Res.* 2018; 46: D608–D617
- [34] Palmer A, Phapale P, Chernyavsky I et al. FDR-controlled metabolite annotation for high-resolution imaging mass spectrometry. *Nat Meth* 2017; 14: 57–60
- [35] Vinaixa M, Schymanski EL, Neumann S et al. Mass spectral databases for LC/MS- and GC/MS-based metabolomics: State of the field and future prospects. *Trend Anal Chem* 2016; 78: 23–35
- [36] Ceglarek U, Leichtle A, Brugel M et al. Challenges and developments in tandem mass spectrometry based clinical metabolomics. *Mol Cell Endocrinol* 2009; 301: 266–271
- [37] Bowen BP, Northen TR. Dealing with the unknown: Metabolomics and metabolite atlases. *J Am Soc Mass Spectrom* 2010; 21: 1471–1476
- [38] Alexandrov T. MALDI imaging mass spectrometry: Statistical data analysis and current computational challenges. *BMC Bioinformatics* 2012; 13 (Suppl 16) : S11
- [39] Galli M, Zoppis I, Smith A et al. Machine learning approaches in MALDI-MSI: Clinical applications. *Expert Rev Proteomics* 2016; 13: 685–696
- [40] Balluff B, Buck A, Martin-Lorenzo M et al. Integrative clustering in mass spectrometry imaging for enhanced patient stratification. *Proteomics Clin Appl* 2019; 13: e1800137
- [41] Leuschner J, Schmidt M, Fernsel P et al. Supervised non-negative matrix factorization methods for MALDI imaging applications. *Bioinformatics* 2019; 35: 1940–1947
- [42] Abdelmoula WM, Balluff B, Englert S et al. Data-driven identification of prognostic tumor subpopulations using spatially mapped t-SNE of mass spectrometry imaging data. *Proc Natl Acad Sci USA* 2016; 113: 12244–12249
- [43] Balluff B, Rauser S, Ebert MP et al. Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease. *Gastroenterology* 2012; 143: 544–549.e542
- [44] Kurreck A, Vandergrift LA, Fuss TL et al. Prostate cancer diagnosis and characterization with mass spectrometry imaging. *Prostate Cancer Prostatic Dis* 2018; 21: 297–305
- [45] Quanico J, Franck J, Wisztorski M et al. Progress and potential of imaging mass spectrometry applied to biomarker discovery. *Methods Mol Biol* 2017; 1598: 21–43

- [46] McDonnell LA, Angel PM, Lou S et al. Mass spectrometry imaging in cancer research: Future perspectives. *Adv Cancer Res* 2017; 134: 283–290
- [47] Balluff B, Hanselmann M, Heeren RM. Mass spectrometry imaging for the investigation of intratumor heterogeneity. *Adv Cancer Res* 2017; 134: 201–230
- [48] Murakami M, Rhayem Y, Kunzke T et al. In situ metabolomics of aldosterone-producing adenomas. *JCI Insight* 2019; 4: pii 130356. doi: 10.1172/jci.insight.130356
- [49] Sugiura Y, Takeo E, Shimma S et al. Aldosterone and 18-oxocortisol coaccumulation in aldosterone-producing lesions. *Hypertension* 2018; 72: 1345–1354
- [50] Manier ML, Spraggins JM, Reyzer ML et al. A derivatization and validation strategy for determining the spatial localization of endogenous amine metabolites in tissues using MALDI imaging mass spectrometry. *J Mass Spectrom* 2014; 49: 665–673
- [51] Kaya I, Brulls SM, Dunevall J et al. On-Tissue Chemical Derivatization of Catecholamines Using 4-(N-Methyl)pyridinium Boronic Acid for ToF-SIMS and LDI-ToF Mass Spectrometry Imaging. *Anal Chem* 2018; 90: 13580–13590
- [52] Takeo E, Sugiura Y, Uemura T et al. Tandem mass spectrometry imaging reveals distinct accumulation patterns of steroid structural isomers in human adrenal glands. *Anal Chem* 2019; 91: 8918–8925
- [53] Cobice DF, Mackay CL, Goodwin RJ et al. Mass spectrometry imaging for dissecting steroid intracrinology within target tissues. *Anal Chem* 2013; 85: 11576–11584
- [54] Zhang Z, Sugiura Y, Mune T et al. Immunohistochemistry for aldosterone synthase CYP11B2 and matrix-assisted laser desorption ionization imaging mass spectrometry for in-situ aldosterone detection. *Curr Opin Nephrol Hypertens* 2019; 28: 105–112
- [55] Malmberg P, Jennische E, Nilsson D et al. High-resolution, imaging TOF-SIMS: novel applications in medical research. *Anal Bioanal Chem* 2011; 399: 2711–2718
- [56] Wu C, Ifa DR, Manicke NE et al. Molecular imaging of adrenal gland by desorption electrospray ionization mass spectrometry. *Analyst* 2010; 135: 28–32
- [57] Wang X, Han J, Pan J et al. Comprehensive imaging of porcine adrenal gland lipids by MALDI-FTMS using quercetin as a matrix. *Anal Chem* 2014; 86: 638–646
- [58] Dufresne M, Masson JF, Chaurand P. Sodium-doped gold-assisted laser desorption ionization for enhanced imaging mass spectrometry of triacylglycerols from thin tissue sections. *Anal Chem* 2016; 88: 6018–6025
- [59] Stoeckli M, Staab D, Schweitzer A et al. Imaging of a beta-peptide distribution in whole-body mice sections by MALDI mass spectrometry. *J Am Soc Mass Spectrom* 2007; 18: 1921–1924
- [60] Khatib-Shahidi S, Andersson M, Herman JL et al. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. *Anal Chem* 2006; 78: 6448–6456
- [61] Chaurand P, Cornett DS, Angel PM et al. From whole-body sections down to cellular level, multiscale imaging of phospholipids by MALDI mass spectrometry. *Mol Cell Proteomics* 2011; 10: O110.004259
- [62] Luo Z, He J, Chen Y et al. Air flow-assisted ionization imaging mass spectrometry method for easy whole-body molecular imaging under ambient conditions. *Anal Chem* 2013; 85: 2977–2982
- [63] Guignat L, Bertherat J. The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline: Commentary from a European perspective. *Eur J Endocrinol* 2010; 163: 9–13
- [64] Duan K, Mete O. Clinicopathologic correlates of primary aldosteronism. *Arch Pathol Lab Med* 2015; 139: 948–954
- [65] Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of adrenal Cushing's syndrome. *J Clin Pathol* 2015; 68: 175–186
- [66] Erickson LA, Rivera M, Zhang J. Adrenocortical carcinoma: review and update. *Adv Anat Pathol* 2014; 21: 151–159
- [67] Ctvrtlik F, Koranda P, Tichy T. Adrenal disease: A clinical update and overview of imaging. A review. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2014; 158: 23–34
- [68] Jochmanova I, Pacak K. Pheochromocytoma: The first metabolic endocrine cancer. *Clin Cancer Res* 2016; 22: 5001–5011
- [69] Lenders JWM, Williams TA, Reincke M et al. Diagnosis of endocrine disease: 18-Oxocortisol and 18-hydroxycortisol: Is there clinical utility of these steroids? *Eur J Endocrinol* 2018; 178: R1–R9
- [70] Arlt W, Lang K, Sitch AJ et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. *JCI Insight* 2017; 2: pii 93136. doi: 10.1172/jci.insight.93136. eCollection 2017 Apr 20
- [71] Gerards J, Heinrich DA, Adolf C et al. Impaired glucose metabolism in primary aldosteronism is associated with cortisol cosecretion. *J Clin Endocrinol Metab* 2019; 104: 3192–3202
- [72] Sun N, Meyer LS, Feuchtinger A et al. Mass spectrometry imaging establishes 2 distinct metabolic phenotypes of aldosterone-producing cell clusters in primary aldosteronism. *Hypertension* 2020; 75: 634–644
- [73] Lanekoff I, Kurczy ME, Hill R et al. Time of flight mass spectrometry imaging of samples fractured in situ with a spring-loaded trap system. *Anal Chem* 2010; 82: 6652–6659
- [74] Roddy TP, Cannon DM Jr., Ostrowski SG et al. Identification of cellular sections with imaging mass spectrometry following freeze fracture. *Anal Chem* 2002; 74: 4020–4026
- [75] Roddy TP, Cannon DM Jr., Meserole CA et al. Imaging of freeze-fractured cells with in situ fluorescence and time-of-flight secondary ion mass spectrometry. *Anal Chem* 2002; 74: 4011–4019
- [76] Lovric J, Dunevall J, Larsson A et al. Nano secondary ion mass spectrometry imaging of dopamine distribution across nanometer vesicles. *ACS Nano* 2017; 11: 3446–3455
- [77] Mohammadi AS, Li X, Ewing AG. Mass spectrometry imaging suggests that cisplatin affects exocytotic release by alteration of cell membrane lipids. *Anal Chem* 2018; 90: 8509–8516